Interna TX

Executive Summary

Interna Therapeutics (Interna TX) is an Israeli biotech company developing a novel Molecular Nano Motor (MNM) platform designed to overcome a key limitation of current therapeutics—intracellular delivery of macromolecules. By leveraging the intrinsic electrical potential of cell membranes, the MNM conjugates to cargo such as DNA, RNA, proteins, and peptides, enabling efficient cytoplasmic entry. This technology addresses a wide range of diseases, with initial focus on infectious and non‑infectious respiratory conditions. Founded in 2020, the company has raised $10.25 million and is currently in Phase 1 development. Its platform holds promise for unlocking previously undruggable targets and improving the efficacy of biologics. Interna TX's approach is differentiated by its physical mechanism of action, which may offer advantages over viral vectors and lipid nanoparticles in terms of safety, tissue targeting, and payload versatility. The company is advancing its lead candidate through early clinical trials, with initial data expected to provide proof‑of‑mechanism and safety. Success in these trials could validate the platform and attract further investment or partnerships. However, as a preclinical/Phase 1 company, execution risk remains high, and the timeline to commercialization is extended. The conviction score reflects the early stage but acknowledges the potential impact of the platform if successfully translated.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 interim safety and tolerability data readout50% success
• Q3 2026Strategic partnership or licensing deal for respiratory indications30% success
• Q4 2026Series B funding round to support Phase 2 preparations40% success